Who is sponsoring NCT03515694?

NCT03515694 is sponsored by Erasme University Hospital.

What drugs are being tested in NCT03515694?

Interventions in NCT03515694: Sugammadex Injection [Bridion].

What condition does NCT03515694 study?

NCT03515694 studies Time of a TOF Ratio >0,9.

Is NCT03515694 still recruiting?

NCT03515694 is currently completed. Last updated 15 February 2019.

Last reviewed 2019-02-15 · How we verify

NCT03515694

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Minimal Optimal Dose of Sugammadex in Elective Surgery

Completed Phase 4 Last updated 15 February 2019

What this trial tests

Phase 4 trial testing Sugammadex Injection [Bridion] in Time of a TOF Ratio >0,9 in 40 participants. Completed in 30 September 2018.

Timeline

3 April 2018

Primary endpoint
30 September 2018

30 September 2018

Quick facts

Lead sponsor	Erasme University Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	3 April 2018
Primary completion	30 September 2018
Estimated completion	30 September 2018
Sites	1 location across Belgium

Drugs / interventions tested

Sugammadex Injection [Bridion] — full drug profile →

Conditions studied

Time of a TOF Ratio >0,9 — all drugs for Time of a TOF Ratio >0,9 →

Sponsor

Erasme University Hospital

Who can join

18 and older, any sex, with Time of a TOF Ratio >0,9. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Time of appearance of TOF Ratio \>0,9 with different doses of Sugammadex

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sugammadex Injection [Bridion]

Trials testing the same drug.

NCT03087513 — A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo · Phase 4 · completed
NCT03229486 — Effect of Sugammadex vs. Neostigmine/Glycopyrrolate on Pediatric Emergence Delirium in Sevoflurane-rocuronium Anesthesia · Phase 4 · completed

Other Erasme University Hospital trials

Trials by the same sponsor.

NCT07532733 — Respiratory and Haemodynamic Effects of Conscious Sedation With Dexmedetomidine for a TAVI Procedure · NA · not yet recruiting
NCT07532681 — Effect of Early Versus Late Surgical Intercostal Block on Postoperative Pain Relief Following Video-Assisted Thoracic Su · NA · not yet recruiting
NCT07457879 — Impact of the Reimbursement of Fibrinogen in Cardiac Surgery · not yet recruiting
NCT07184593 — Nucleosome Monitoring Relevance for Outcome Prediction in Critically Ill Patients · not yet recruiting
NCT07369232 — Cerebral Hemodynamic Effects of Oxygen and Antioxidants (CHEOXANT) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03515694 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erasme University Hospital
Last refreshed: 15 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03515694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing